Our findings highlight that INK4 proteins are not only differentially expressed among AML subtypes but also contribute to CDK6-targeted therapeutic efficacy.Therefore, they can be considered as predictive indicators of treatment success and guide further strategies. Here, CDK6 is linked to acute myeloid leukemia.